Synapse - Works

Results (4640)

A phase 1/2 study of GB1275, a novel CD11b modulator, as monotherapy and with an anti-PD-1 antibody in specified advanced solid tumors or with chemotherapy in metastatic pancreatic cancer (mPDAC)

Meeting Abstract

Bendell, J.; Rasco, D.; Park, W.; Zhou, L.; Galkin, A.; Slee, D.; Carter, L.; Nickle, D.; Tran, R.; Li, J.; more...
Journal for ImmunoTherapy of Cancer (2019)

Fulltext@MSK | Save

Outcomes based on plasma biomarkers for the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Parnis, F.; Rimassa, L.; Kelley, R. K.; Meyer, T.; Ryoo, B. Y.; Merle, P.; Park, J. W.; Blanc, J. F.; Lim, H. Y.; Tran, A.; more...
Asia-Pacific Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

BEACON CRC: A randomized, 3-Arm, phase 3 study of encorafenib (ENCO) and cetuximab (CETUX) with or without binimetinib (BINI) versus choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer

Meeting Abstract

Desai, J.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Ciardello, F.; Gollerkeri, A.; Maharry, K.; more...
Asia-Pacific Journal of Clinical Oncology (2019)

Fulltext@MSK | Save

FIGHT-202: A phase II study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)

Meeting Abstract

Vogel, A.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A. S.; Borad, M. J.; Gallinson, D.; Murphy, A. G.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Health-related quality of life (HRQoL) impact of pembrolizumab (P) versus chemotherapy (C) as first-line (1L) treatment in PD-L1-positive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Meeting Abstract

Van Cutsem, E.; Valderrama, A.; Bang, Y. J.; Fuchs, C.; Shitara, K.; Janjigian, Y. Y.; Qin, S.; Larson, T.; Shankaran, V.; Stein, S.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)

Meeting Abstract

Tabernero, J.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Loupakis, F.; Sang Hong, Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)

Meeting Abstract

Yau, T.; Park, J. W.; Finn, R. S.; Cheng, A. L.; Mathurin, P.; Edeline, J.; Kudo, M.; Han, K. H.; Harding, J. J.; Merle, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation

Meeting Abstract

Abou-Alfa, G. K.; Macarulla Mercade, T.; Javle, M.; Kelley, R. K.; Lubner, S.; Adeva, J.; Cleary, J. M.; Catenacci, D. V.; Borad, M. J.; Bridgewater, J. A.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

POLO: Time to treatment discontinuation and subsequent therapies following maintenance olaparib for patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC)

Meeting Abstract

Van Cutsem, E.; Golan, T.; Hammel, P.; Reni, M.; Macarulla, T.; Hall, M. J.; Park, J. O.; Hochhauser, D.; Arnold, D.; Oh, D. Y.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save

Preliminary safety and pharmacokinetics of a new lysosomotropic oral agent, GNS561, in a first-in-human study in advanced primary liver cancer patients

Meeting Abstract

Awada, A. H.; Harding, J. J.; Kotecki, N.; Aftimos, P. G.; Decaens, T.; Dreyer, C.; Ansaldi, C.; Rachid, M.; Serdjebi, C.; Halfon, P.; more...
Annals of Oncology (2019)

Fulltext@MSK | Save